Akebia Therapeutics (AKBA) Total Current Liabilities (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Total Current Liabilities data on file, last reported at $173.9 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $173.9 million, up 90.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $173.9 million (up 90.61% YoY), and the FY2025 annual result was $162.9 million, up 101.37% from the prior year.
• Total Current Liabilities advanced to $173.9 million in Q1 2026 per AKBA's latest filing, from $162.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $258.5 million in Q1 2022 and troughed at $65.7 million in Q3 2024.
• A 5-year average of $128.1 million and a median of $107.3 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities sank 66.09% in 2023, then soared 102.98% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $129.5 million in 2022, then slipped by 22.9% to $99.9 million in 2023, then slipped by 18.98% to $80.9 million in 2024, then jumped by 101.37% to $162.9 million in 2025, then climbed by 6.72% to $173.9 million in 2026.
• Business Quant data shows AKBA's Total Current Liabilities at $173.9 million in Q1 2026, $162.9 million in Q4 2025, and $133.4 million in Q3 2025.